Cyclosporine News and Research

RSS

Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.

Schering-Plough announces ZETIA spproved in Japan

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ZETIA (ezetimibe), a novel cholesterol-lowering agent that inhibits the absorption of cholesterol in the intestine.

20 Apr 2007

New anti-rejection medication 6-month results for heart transplant recipients to be released

New clinical trial results for heart transplant patients will be released at the upcoming International Society for Heart and Lung Transplantation (ISHLT) 27th Annual Meeting and Scientific Sessions at the Hilton San Francisco, April 25-28, 2007.

20 Apr 2007

Drug infliximab may help ease ulcerative colitis

In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work.

12 Sep 2006

Genotoxic bacteria in the digestive tract

Escherichia coli is a commensal bacterium, which lives peacefully in our digestive tract. However, certain strains are pathogenic and are frequently incriminated in a broad spectrum of infections, affecting both farmed animals and humans (diarrhoea, urinary tract infections, food poisoning, septicaemia, neonatal meningitis, etc.).

16 Aug 2006

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.

26 Jul 2006

Researchers increase bone mass by tweaking the shape of a regulatory protein

Howard Hughes Medical Institute (HHMI) researchers at Stanford University have found that they can increase bone mass in mice by tweaking the shape of a regulatory protein.

6 Jun 2006

Single dose of stem cells produce robust behavioral recovery in animal models for stroke, cerebral palsy

A single dose of adult donor stem cells given to animals that have neurological damage similar to that experienced by adults with a stroke or newborns with cerebral palsy can significantly enhance recovery from these types of injuries, researchers say.

11 Apr 2006

Trends over a decade of pediatric liver transplantation in the U.S.

A new study on children undergoing liver transplants found that although innovative transplant techniques have been developed in recent years, the waitlist times for pediatric transplant candidates have increased compared to the early 1990s.

6 Apr 2006

Sirolimus reduces risk of cancer in kidney transplant patients

A new study published in this month's issue of the Journal of the American Society of Nephrology shows that the risk of cancer in kidney transplant recipients was reduced by more than 50% at five years post transplantation in those patients who were treated with sirolimus following withdrawal of cyclosporine at three months.

13 Feb 2006

New version of diet drug not suitable for some

According to the U.S. Food and Drug Administration a version of the diet drug Xenical, which will be available without a prescription, may be not be suitable for some people.

23 Jan 2006

Lung transplant survival extended by Cyclosporine

According to a new study in the U.S., lung transplant patients live longer when they inhale the rejection-fighting drug Cyclosporine.

16 Jan 2006

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.

5 Jan 2006

Experimental immunusuppressant drug preserves transplanted kidneys

An international team of transplant physicians has shown that the investigational drug belatacept (LEA29Y) preserves transplanted kidney function as effectively as cyclosporine, the drug most commonly used to prevent the immune system from rejecting transplanted organs.

24 Aug 2005

New drug that selectively blocks immune responses protects kidneys after transplant

In an international clinical trial, a new drug that selectively blocks immune responses has proved as effective in preventing acute kidney transplant rejection as cyclosporine, the standard anti-rejection treatment.

24 Aug 2005

Daclizumab effective at reducing organ rejection and risk of infection in heart transplant patients

A new study shows that a drug, called daclizumab, is effective at reducing organ rejection and risk of infection in heart transplant patients. The multi-center study by cardiologists from the United States, Sweden, Germany and Canada will be published in the June 30 issue of The New England Journal of Medicine.

30 Jun 2005

Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants

A new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ also known as FK506) had significant anti-rejection benefits for heart transplant patients over other combinations.

22 May 2005

High levels of immunosuppressant may lead to tumor recurrence

A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.

22 Apr 2005

Cyclosporine inhalation solution (CyIS) significantly improves long-term survival in lung-transplant patients

Data presented for the first time at the 25th Annual Meeting and Scientific Session of the International Society for Heart and Lung Transplantation (ISHLT) show that cyclosporine inhalation solution (CyIS) significantly improves long-term survival in lung-transplant patients compared to placebo.

10 Apr 2005

Alcohol relapse adversely affects liver transplant survival

A new study on how alcohol relapse affects survival rates after liver transplants found that it adversely affected survival rates only after 10 years. The decrease in survival rates may, however, be due to other alcohol-related diseases.

22 Mar 2005

FDA issues information on the risks and benefits of Crestor

The U.S. Food and Drug Administration (FDA), today issued public health advice, patient information, and professional healthcare information on the risks and benefits of Crestor (Rosuvastatin calcium), a cholesterol-lowering drug.

2 Mar 2005